About Endocyte |
||||
Great progress has been made in the development of new drugs to treat cancer and other serious illness. However, these therapies are often administered at suboptimal doses because of their side effects on healthy tissues. The value of these therapies is further diminished because of the inability to predict (in advance) if a patient will respond to a particular therapy. Endocyte is addressing both of these issues using a new "drug guidance" technology. Drug Guidance Systems Endocyte's novel “drug guidance system” is designed to improve the specificity, safety and efficacy of existing drugs by targeting them directly at diseased cells. Our technology can be used to deliver a variety of drug therapies from small molecule cancer drugs to larger proteins and RNA-based therapies. Predicitve Medicine Endocyte is also developing powerful companion diagnostic agents (such as EC20 and EC0652) that are designed to predict (in advance) if a patient will respond to our drug therapy. By linking our drug guidance system to a diagnostic imaging agent, we can generate a patient specific targeting profile to help identify likely responders (click to see image). Strong Clinical Stage Pipeline Today, Endocyte has 5 targeted cancer drugs in clinical trials. We believe our patented technology may also have application in developing better drugs to treat diseases such as rheumatoid arthritis, osteoarthritis, and atherosclerosis. This proprietary technology is being used today by a number of drug companies in collaboration with Endocyte, including Bristol-Myers Squibb..
|
||||
|
"Our mission is to make existing drugs safer and more effective by targeting them directly at diseased cells. Our unique approach to drug targeting and predictive medicine may open new opportunities to treat diseases."
Ron Ellis
CEO/President
